ESC Premium Access

Challenges in targeting residual risk in diabetic patients, post ACS

Topic: Clinical
Organised by PACE-CME, supported with an educational grant provided by Resverlogix

Presentation

About the speaker

Professor Peter Libby

Brigham and Women's Hospital, Boston (United States of America)
28 presentations
2 followers

4 more presentations in this session

Introduction

Speaker: Professor U. Landmesser (Berlin, DE)

Thumbnail

BET inhibition, an epigenetic pathway: how could BET inhibition modulate atherothrombotic risk

Speaker: Professor J. Jukema (Leiden, NL)

Thumbnail

Clinical update on BET inhibition: the patient profile that may benefit from BET inhibition?

Speaker: Professor K. Ray (London, GB)

Thumbnail

Discussion

Speaker: Professor U. Landmesser (Berlin, DE) Professor K. Ray (London, GB)

Thumbnail

Access the full session

Epigenetics: a new pathway to tackle residual risk?

Speakers: Professor P. Libby, Professor U. Landmesser, Professor J. Jukema, Professor K. Ray, Professor U. Landmesser...
Thumbnail

About the event

Image

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk